Latest research on Linezolid

Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis.

Latest findings

Of interest, the MIC of MRSA to Linezolid from our patient’s isolate was 4 μg/mL, three dilutions greater than the isolate in the prior case report (MIC=0.5 μg/mL). [source, 2002]
Patient 2’s treatment was changed from empiric Vancomycin to Linezolid for VRE bacteremia without Linezolid being part of her initial susceptibility data. [source, 2002]
Only after the patient died did the requested sensitivities to Linezolid became available. [source, 2002]
Had Linezolid been part of the initial susceptibility data, other therapies most likely would have been pursued since the isolate was resistant to Linezolid. [source, 2002]
In a published case series involving Linezolid for 15 patients with VRE infections, mortality was noted to be very high at long-term followup (6). [source, 2002]
Second, other options were pursued before the initiation of Linezolid, which may have inadvertently contributed to increased illness and death because of the delay in giving Linezolid therapy. [source, 2002]
These data, in addition to these recent experiences, have led us to routinely conduct susceptibility testing of Linezolid and quinupristin/dalfopristin to VRE obtained from any sterile site. [source, 2002]
Previously, susceptibility data of Linezolid and quinupristin/dalfopristin to VRE or MRSA were not routinely conducted unless specifically requested. [source, 2002]
Our current practice includes obtaining tests of a VRE isolate’s susceptibility to Linezolid and quinupristin/dalfopristin as routine practice if the isolate is obtained from any sterile site. [source, 2002]
Because of the large number of S. aureus isolates resistant to Methicillin submitted to the microbiology laboratory annually, and because Linezolid nonsusceptibility to clinical isolates of MRSA has only been reported once (9), we continue to conduct susceptibility testing of Linezolid and quinupristin/dalfopristin to MRSA isolates only when requested. [source, 2002]